WO2013022740A3 - Gpr35 ligands and the uses thereof - Google Patents

Gpr35 ligands and the uses thereof Download PDF

Info

Publication number
WO2013022740A3
WO2013022740A3 PCT/US2012/049483 US2012049483W WO2013022740A3 WO 2013022740 A3 WO2013022740 A3 WO 2013022740A3 US 2012049483 W US2012049483 W US 2012049483W WO 2013022740 A3 WO2013022740 A3 WO 2013022740A3
Authority
WO
WIPO (PCT)
Prior art keywords
gpr35
ligands
risk
reducing
disclosed
Prior art date
Application number
PCT/US2012/049483
Other languages
French (fr)
Other versions
WO2013022740A2 (en
Inventor
Huayun Deng
Ye Fang
Haibei Hu
Original Assignee
Corning Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corning Incorporated filed Critical Corning Incorporated
Publication of WO2013022740A2 publication Critical patent/WO2013022740A2/en
Publication of WO2013022740A3 publication Critical patent/WO2013022740A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Disclosed are compositions and methods for reducing the risk of and/or treatment of diseases which are pathophysiologically related to GPR35, and/or GPR35-hERG signaling complex. For example, disclosed are compounds for reducing the risk of and/or treating diseases which are pathophysiologically related to GPR35 in a subject.
PCT/US2012/049483 2011-08-05 2012-08-03 Gpr35 ligands and the uses thereof WO2013022740A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161515409P 2011-08-05 2011-08-05
US61/515,409 2011-08-05

Publications (2)

Publication Number Publication Date
WO2013022740A2 WO2013022740A2 (en) 2013-02-14
WO2013022740A3 true WO2013022740A3 (en) 2013-05-10

Family

ID=47669171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/049483 WO2013022740A2 (en) 2011-08-05 2012-08-03 Gpr35 ligands and the uses thereof

Country Status (1)

Country Link
WO (1) WO2013022740A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014163512A1 (en) * 2013-04-05 2014-10-09 Manuka Health New Zealand Limited Therapeutic compositions comprising extracts of propolis and uses thereof
EP3360875A1 (en) 2013-05-28 2018-08-15 Astrazeneca AB Chemical compounds
AU2015290284A1 (en) * 2014-07-18 2017-01-19 Manuka Health New Zealand Limited Propolis and extracts thereof for the treatment of skin cancers and improvement of skin health
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
WO2018210658A1 (en) * 2017-05-15 2018-11-22 Basf Se Heteroaryl compounds as agrochemical fungicides
JP7323539B2 (en) 2017-11-20 2023-08-08 スティングセラ インコーポレイテッド Oxoacridinyl acetic acid derivative and method of use
US11414387B2 (en) 2017-11-20 2022-08-16 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
CN111285790A (en) * 2018-12-06 2020-06-16 泰州医药城国科化物生物医药科技有限公司 3-carboxycoumarin derivative capable of serving as GPR35 agonist, preparation method and application
CN109602735A (en) * 2018-12-07 2019-04-12 广州市妇女儿童医疗中心 The application of the drug and alpha-cyano -4- hydroxycinnamic acid of prevention and/or treatment intestines problem
CR20220316A (en) 2019-12-06 2022-10-07 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
AR126073A1 (en) 2021-06-04 2023-09-06 Vertex Pharma N-(HYDROXYALKYL(HETERO)ARYL)TETRAHYDROFURAN CARBOXAMIDES AS SODIUM CHANNEL MODULATORS
WO2023078252A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005059546A2 (en) * 2003-12-12 2005-06-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
US20070077602A1 (en) * 2004-05-26 2007-04-05 Leonard James N GPR35 and modulators thereof for the treatment of metabolic-related disorders
WO2011011235A1 (en) * 2009-07-22 2011-01-27 Temple University - Of The Commonwealth System Of Higher Education Treatment of disorders associated with g protein-coupled receptor 35 (gpr35)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005059546A2 (en) * 2003-12-12 2005-06-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
US20070077602A1 (en) * 2004-05-26 2007-04-05 Leonard James N GPR35 and modulators thereof for the treatment of metabolic-related disorders
WO2011011235A1 (en) * 2009-07-22 2011-01-27 Temple University - Of The Commonwealth System Of Higher Education Treatment of disorders associated with g protein-coupled receptor 35 (gpr35)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DUBE ET AL.: "Assessment of the Carcinogenic Potential of a Proposed Food Coloring Additive Laccaic Acid, Using Short-Term Assays", CELL BIOLOGY AND TOXICOLOGY, vol. 1, no. 1, 1984 *
TANIGUCHI ET AL.: "5-Nitro-2-(3-Phenylpropylamino)benzoic Acid Is a GPR35 Agonist", PHARMACOLOGY, vol. 82, 2008, pages 245 - 249. *
WANG ET AL.: "Kynurenic Acid as a Ligand for Orphan G Protein-coupled Receptor GPR35", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 31, 4 August 2006 (2006-08-04), pages 22021 - 22028 *
ZHAO ET AL.: "Targeting of the Orphan Receptor GPR35 by Pamoic Acid: A Potent Activator of Extracellular Signal-Regulated Kinase and beta-Arrestin2 with Antinociceptive Activity", MOL PHARMACOL, vol. 78, 2010, pages 560 - 568 *

Also Published As

Publication number Publication date
WO2013022740A2 (en) 2013-02-14

Similar Documents

Publication Publication Date Title
WO2013022740A3 (en) Gpr35 ligands and the uses thereof
WO2012062925A3 (en) Compounds and methods for treating pain
HK1214168A1 (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
CA2865011C (en) Methods and compositions for treating huntington's disease
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MD20140035A2 (en) Method for treating hepatitis C virus
CA2900779C (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
WO2013021279A3 (en) Highly galactosylated antibodies
PL2672966T3 (en) Pharmaceutical composition, methods for treating and uses thereof
RS61827B1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2012012278A3 (en) Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex
WO2012129341A3 (en) Disease detection in plants
WO2013098416A3 (en) Pain relief compounds
HK1215173A1 (en) Methods of treating s. aureus-associated diseases
WO2013134407A3 (en) Procaspase 3 activation by combination therapy
EP2729156A4 (en) Methods and compositions useful for treating fitzpatrick type iv, v or vi skin
IL245849A0 (en) Process for the preparation of complexes of 68ga.
HK1192726A1 (en) 1,2,4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases 124--5-
PL3260865T3 (en) Method for the treatment of blood, blood products and organs
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MX2014009244A (en) A composition and use thereof in the treatment of anal rhagades.
WO2014064609A3 (en) HERBAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF TNF-α MEDIATED DISEASES
GB2514940B (en) Process for the treatment of ash, treated ash thus obtained and uses of treated ash
WO2013155465A8 (en) Substituted xanthine derivatives
WO2013163562A3 (en) Compositions and methods for treating ptsd and related diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12822443

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12822443

Country of ref document: EP

Kind code of ref document: A2